09:55 AM EST, 12/18/2024 (MT Newswires) -- Astrazeneca's ( AZN ) rare disease group Alexion Pharma Canada said Wednesday it signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for Koselugo to treat pediatric patients aged at least two years with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

With the agreement in place, individual provinces and territories in Canada may now start the procedure to list Koselugo on their formularies, Alexion Pharma said.

Financial terms were not disclosed.

Price: 66.36, Change: -0.82, Percent Change: -1.22